These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 25975816)

  • 21. Pharmacokinetics of a fixed-dose glimepiride/sustained-release metformin combination.
    Kim KP; Lim KS; Kim BH; Shin HS; Cho JY; Shin SG; Jang IJ; Yu KS
    Int J Clin Pharmacol Ther; 2012 Feb; 50(2):142-9. PubMed ID: 22257580
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral antidiabetic drugs: bioavailability assessment of fixed-dose combination tablets of pioglitazone and metformin. Effect of body weight, gender, and race on systemic exposures of each drug.
    Karim A; Slater M; Bradford D; Schwartz L; Zhao Z; Cao C; Laurent A
    J Clin Pharmacol; 2007 Jan; 47(1):37-47. PubMed ID: 17192500
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus.
    Seino Y; Inagaki N; Haneda M; Kaku K; Sasaki T; Fukatsu A; Ubukata M; Sakai S; Samukawa Y
    J Diabetes Investig; 2015 Jul; 6(4):443-53. PubMed ID: 26221523
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of Reduced Renal Function on the Glucose-Lowering Effects of Luseogliflozin, a Selective SGLT2 Inhibitor, Assessed by Continuous Glucose Monitoring in Japanese Patients with Type 2 Diabetes Mellitus.
    Jinnouchi H; Nozaki K; Watase H; Omiya H; Sakai S; Samukawa Y
    Adv Ther; 2016 Mar; 33(3):460-79. PubMed ID: 26846284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of Empagliflozin and Pioglitazone After Coadministration in Healthy Volunteers.
    Macha S; Mattheus M; Pinnetti S; Broedl UC; Woerle HJ
    Clin Ther; 2015 Jul; 37(7):1503-16. PubMed ID: 26051874
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.
    Aoki K; Kamiyama H; Yoshimura K; Shibuya M; Masuda K; Terauchi Y
    Acta Diabetol; 2012 Jun; 49(3):225-30. PubMed ID: 21898126
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Truncated areas under the curve in the assessment of pioglitazone bioequivalence. Data from a single-center, single-dose, randomized, open-label, 2-way cross-over bioequivalence study of two formulations of pioglitazone 45 mg tablets under fasting conditions.
    Almeida S; Filipe A; Neves R; Pinho C; Pedroso P; Castillo A; Trabelsi F
    Arzneimittelforschung; 2011; 61(1):32-9. PubMed ID: 21355444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized, Controlled, Thorough QT/QTc Study Shows Absence of QT Prolongation with Luseogliflozin in Healthy Japanese Subjects.
    Kumagai Y; Hasunuma T; Sakai S; Ochiai H; Samukawa Y
    PLoS One; 2015; 10(10):e0139873. PubMed ID: 26444986
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Strategy for assessing potential drug-drug interactions of a concomitant agent against a drug absorbed via an intestinal transporter in humans.
    Mizuno-Yasuhira A; Nakai Y; Gunji E; Uchida S; Takahashi T; Kinoshita K; Jingu S; Sakai S; Samukawa Y; Yamaguchi J
    Drug Metab Dispos; 2014 Sep; 42(9):1456-65. PubMed ID: 25005603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function.
    Alba M; Ahrén B; Inzucchi SE; Guan Y; Mallick M; Xu L; O'Neill EA; Williams-Herman DE; Kaufman KD; Goldstein BJ
    Diabetes Obes Metab; 2013 Dec; 15(12):1101-10. PubMed ID: 23782502
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety, pharmacokinetics, and pharmacodynamics of single and multiple luseogliflozin dosing in healthy Japanese males: a randomized, single-blind, placebo-controlled trial.
    Sasaki T; Seino Y; Fukatsu A; Sakai S; Samukawa Y
    Adv Ther; 2014 Mar; 31(3):345-61. PubMed ID: 24535625
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects.
    Mistry GC; Bergman AJ; Luo WL; Cilissen C; Haazen W; Davies MJ; Gottesdiener KM; Wagner JA; Herman GA
    J Clin Pharmacol; 2007 Feb; 47(2):159-64. PubMed ID: 17244766
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers.
    Brand T; Macha S; Mattheus M; Pinnetti S; Woerle HJ
    Adv Ther; 2012 Oct; 29(10):889-99. PubMed ID: 23054692
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of eslicarbazepine acetate on the pharmacokinetics of metformin in healthy subjects.
    Rocha JF; Vaz-da-Silva M; Almeida L; Falcão A; Nunes T; Santos AT; Martins F; Fontes-Ribeiro C; Macedo T; Soares-da-Silva P
    Int J Clin Pharmacol Ther; 2009 Apr; 47(4):255-61. PubMed ID: 19356391
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Luseogliflozin: first global approval.
    Markham A; Elkinson S
    Drugs; 2014 Jun; 74(8):945-50. PubMed ID: 24848756
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic comparison of a new sustained-release formulation of glimepiride/metformin 1/500 mg combination tablet and a sustained-release formulation of glimepiride/metformin 2/500 mg combination tablet in healthy Korean male volunteers: a randomized, 2-sequence, 2-period, 2-treatment crossover study.
    Shin KH; Kim SE; Yoon SH; Cho JY; Jang IJ; Shin SG; Yu KS
    Clin Ther; 2011 Nov; 33(11):1809-18. PubMed ID: 22036245
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of simvastatin on the pharmacokinectics of sitagliptin.
    Cerra M; Luo WL; Li SX; Matthews C; O'Neill EA; Wagner JA; Stoch SA; Anderson MS
    J Popul Ther Clin Pharmacol; 2012; 19(3):e356-60. PubMed ID: 23077137
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone.
    Bailey CJ; Green BD; Flatt PR
    Expert Opin Investig Drugs; 2010 Aug; 19(8):1017-25. PubMed ID: 20629618
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic interactions between topiramate and pioglitazone and metformin.
    Manitpisitkul P; Curtin CR; Shalayda K; Wang SS; Ford L; Heald D
    Epilepsy Res; 2014 Nov; 108(9):1519-32. PubMed ID: 25219351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.